clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИclinvest-302Research ArticleБЕЗОПАСНОСТЬ ЛЕКАРСТВDRUG SAFETYРоль мониторинга безопасности лекарственных средств в решении проблемы их рационального использованияОвчинниковаЕ. А.clinvest@mail.ruФедеральное государственное учреждение «Экспертизы средств медицинского применения» МЗ РФ, г. МоскваRussian Federation200326062008048895Copyright © Овчинникова Е.А., 20182018Овчинникова Е.А.Овчинникова Е.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/302мониторинг безопасности лекарствфармаконадзорнежелательные лекарственные реакцииReferencesRequirements for adverse reaction reporting, Geneva, Switzerland: World Health Organization, 1975.Requirements for adverse reaction reporting, Geneva, Switzerland: World Health Organization, 1975.Shear N.H., Del Rosso J.Q., Phillips E., Sullivan J.R., Wolverton S.E. Drug Actions, Interactions, Reactions. Program of the American Academy of Dermatology, Academy 2000, 5.Shear N.H., Del Rosso J.Q., Phillips E., Sullivan J.R., Wolverton S.E. Drug Actions, Interactions, Reactions. Program of the American Academy of Dermatology, Academy 2000, 5.The Institute for Healthcare Improvement, The Quest for Error-Proof Medicine, Drug Benefit, 1997, 9(6), 18-29.The Institute for Healthcare Improvement, The Quest for Error-Proof Medicine, Drug Benefit, 1997, 9(6), 18-29.Classen D.C., Pestotnik S.L., Evans S., et al., Adverse drug events in hospitalized patients: Excess length of stay, extra costs, and attributable mortality, JAMA, 1997, 277, 301-306.Classen D.C., Pestotnik S.L., Evans S., et al., Adverse drug events in hospitalized patients: Excess length of stay, extra costs, and attributable mortality, JAMA, 1997, 277, 301-306.Bates D.W., Cullen D.J., Laird N. et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA, 1995, 274, 29-34.Bates D.W., Cullen D.J., Laird N. et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA, 1995, 274, 29-34.Lazarou J., Pomeranz BH., Corey P.N. Icidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies, JAMA, 1998, 15, 279(15), 1200-1205.Lazarou J., Pomeranz BH., Corey P.N. Icidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies, JAMA, 1998, 15, 279(15), 1200-1205.Lepori V., Perren A., Marone C. Adverse internal medicine drug effects at hospital admission, Schweiz Med Wochenschr, 1999, 19, 129 (24), 915-922.Lepori V., Perren A., Marone C. Adverse internal medicine drug effects at hospital admission, Schweiz Med Wochenschr, 1999, 19, 129 (24), 915-922.Fattinger K., Roos M., Vergeres P., Holenstein C., Kind B., Masche U., Stocker D.N., Braunschweig S., Kullak.Ublick G.A., Galeazzi R.L., Follath F., Gasser T., Meier P.J. Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine, Br. J. Clin. Pharmacol., 2000, 49(2), 158-167.Fattinger K., Roos M., Vergeres P., Holenstein C., Kind B., Masche U., Stocker D.N., Braunschweig S., Kullak.Ublick G.A., Galeazzi R.L., Follath F., Gasser T., Meier P.J. Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine, Br. J. Clin. Pharmacol., 2000, 49(2), 158-167.Lindquist R., Gersema L.M. Understanding and preventing adverse drug events, AACN Clin. Issues, 1998, 9(1), 119-128.Lindquist R., Gersema L.M. Understanding and preventing adverse drug events, AACN Clin. Issues, 1998, 9(1), 119-128.Bates D.W., Spell N., Cullen D.J. et al. The costs of adverse drug events in hospitalized patients, JAMA, 1997, 277, 307-311.Bates D.W., Spell N., Cullen D.J. et al. The costs of adverse drug events in hospitalized patients, JAMA, 1997, 277, 307-311.Naisbitt D.J., Gordon S.F., Pirmohamed M., Park B.K. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment, Drug. Saf. 2000, 23(6), 483-507.Naisbitt D.J., Gordon S.F., Pirmohamed M., Park B.K. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment, Drug. Saf. 2000, 23(6), 483-507.Green C.F., Mottram D.R., Rowe P.H., Pirmohamed M. Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study, J. Clin. Pharm. Ther., 2000, 25 (5), 355-361.Green C.F., Mottram D.R., Rowe P.H., Pirmohamed M. Adverse drug reactions as a cause of admission to an acute medical assessment unit: a pilot study, J. Clin. Pharm. Ther., 2000, 25 (5), 355-361.Schoenemann J., Munter KH., Enayati.Kashani S. Unerwunschte Arzneimittelwirkungen in der klinik, Dtsch. Med. Wochenschr., 1998, 123 (15), 448-452.Schoenemann J., Munter KH., Enayati.Kashani S. Unerwunschte Arzneimittelwirkungen in der klinik, Dtsch. Med. Wochenschr., 1998, 123 (15), 448-452.Leape L.L., Brennan T.A., Laird N. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II, N. Engl. J. Med., 1991, 324, 377-384.Leape L.L., Brennan T.A., Laird N. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II, N. Engl. J. Med., 1991, 324, 377-384.Aparasu R.R., Helgeland D.L. Utilization of ambulatory care services caused by adverse effects of medications in the United States, Manag. Care. Interface., 2000, 13(4), 70-75.Aparasu R.R., Helgeland D.L. Utilization of ambulatory care services caused by adverse effects of medications in the United States, Manag. Care. Interface., 2000, 13(4), 70-75.Астахова А.В., Лепахин В.К. Проблемы безопасности лекарственных средств в России // Фармацевтический мир, 1997, 2, 10-12. 17.Астахова А.В., Лепахин В.К. Проблемы безопасности лекарственных средств в России // Фармацевтический мир, 1997, 2, 10-12. 17.Marshall J.D., Kearns G.L. Developmental pharmacodynamics of cyclosporine. Clin. Pharmacol Ther., 1999, 66, 66-75.Marshall J.D., Kearns G.L. Developmental pharmacodynamics of cyclosporine. Clin. Pharmacol Ther., 1999, 66, 66-75.Dyer K.S,, Woolf A.D. Use of phenothiazines as sedatives in children. What are the risks? Drug Safety, 1999, 21, 81-90.Dyer K.S,, Woolf A.D. Use of phenothiazines as sedatives in children. What are the risks? Drug Safety, 1999, 21, 81-90.Gupta A., Waldhauser L.K. Adverse drug reactions from birth to early childhood. Pediatr. Clin. North. Am., 1997, 44(1), 79-92.Gupta A., Waldhauser L.K. Adverse drug reactions from birth to early childhood. Pediatr. Clin. North. Am., 1997, 44(1), 79-92.Cooper J.W. Adverse drug reactions and interactions in a geriatric nursing home population over 4 years. J. Am. Geriatr. Soc., 1996, 44, 194-197.Cooper J.W. Adverse drug reactions and interactions in a geriatric nursing home population over 4 years. J. Am. Geriatr. Soc., 1996, 44, 194-197.Cooper J.W. Adverse drug reaction hospitalizations of nursing facility residents: a 4-year study. South. Med. J., 1999, 95, 485-490.Cooper J.W. Adverse drug reaction hospitalizations of nursing facility residents: a 4-year study. South. Med. J., 1999, 95, 485-490.Cunningham G., Dodd T.R., Grant D.J., McMurdo M.E., Richards R.M. Drug-related problems in elderly patients admitted to Tayside hospitals, methods for prevention and subsequent reassessment, Age Ageing, 1997, 26(5), 375-82.Cunningham G., Dodd T.R., Grant D.J., McMurdo M.E., Richards R.M. Drug-related problems in elderly patients admitted to Tayside hospitals, methods for prevention and subsequent reassessment, Age Ageing, 1997, 26(5), 375-82.Mannesse C.K., Derkx F.H., de Ridder M.A., Man in’t Veld A.J., van der Cammen T.J. Contribution of adverse drug reactions to hospital admission of older patients, Age Ageing, 2000, 29 (1), 35-39.Mannesse C.K., Derkx F.H., de Ridder M.A., Man in’t Veld A.J., van der Cammen T.J. Contribution of adverse drug reactions to hospital admission of older patients, Age Ageing, 2000, 29 (1), 35-39.Cutroneo P.M., Arcoraci V., Cucinotta G., Inferrera G., Galante F., Sofia A., Ferrera E., Napolitano T., Mazzaglia G., Caputi A.P. Adverse drug reactions in childhood. A drug surveillance study in Sicily, Recenti Prog. Med., 1998, 89(6), 290-295.Cutroneo P.M., Arcoraci V., Cucinotta G., Inferrera G., Galante F., Sofia A., Ferrera E., Napolitano T., Mazzaglia G., Caputi A.P. Adverse drug reactions in childhood. A drug surveillance study in Sicily, Recenti Prog. Med., 1998, 89(6), 290-295.Easton K.L., Parsons B.J., Starr M., Brien J.E. The incidence of drug-related problems as a cause of hospital admissions in children, Med. J. Aust, 1998, 5,169 (7), 356-359.Easton K.L., Parsons B.J., Starr M., Brien J.E. The incidence of drug-related problems as a cause of hospital admissions in children, Med. J. Aust, 1998, 5,169 (7), 356-359.Another kind of drug problem (editorial). Rachelўs environment and health weekly, 1999, 632, 1-2.Another kind of drug problem (editorial). Rachelўs environment and health weekly, 1999, 632, 1-2.Bates D.W., Drugs and adverse drug reactions. How worried should we be? JAMA. 1998, 279, 1216-1217.Bates D.W., Drugs and adverse drug reactions. How worried should we be? JAMA. 1998, 279, 1216-1217.Kvasz M., Allen I.E., Gordon M.J. et al. Adverse drug reactions in hospitalized patients: a critique of a meta-analysis. Med. Gen. Med., April 27, 2000.Kvasz M., Allen I.E., Gordon M.J. et al. Adverse drug reactions in hospitalized patients: a critique of a meta-analysis. Med. Gen. Med., April 27, 2000.Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients, JAMA, 1998, 279, 1200-1205.Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients, JAMA, 1998, 279, 1200-1205.Porter J., Jick H. Drug-related deaths among medical inpatients. JAMA, 1977, 237, 879-881.Porter J., Jick H. Drug-related deaths among medical inpatients. JAMA, 1977, 237, 879-881.Moore N.D., Lecaintre D., Nobet C. Serious ADR in a department of internal medicine. Pharmacoepidemiology and Drug Safety, 1995, 4, 74.Moore N.D., Lecaintre D., Nobet C. Serious ADR in a department of internal medicine. Pharmacoepidemiology and Drug Safety, 1995, 4, 74.Suh D.C., Woodall B.S., Shin S.K. Clinical and economic impact of adverse drug reactions in hospitalized patients, Ann Pharmacother, 2000, 34(12), 1373-1379.Suh D.C., Woodall B.S., Shin S.K. Clinical and economic impact of adverse drug reactions in hospitalized patients, Ann Pharmacother, 2000, 34(12), 1373-1379.Lesar T.S., Briceland L., Stein D.S. Factors related to errors in medication prescribing. JAMA, 1997, 277, 312-317.Lesar T.S., Briceland L., Stein D.S. Factors related to errors in medication prescribing. JAMA, 1997, 277, 312-317.Anderson J.G., Jay S.J., Anderson M., Hunt T.J. Evaluating the potential effectiveness of using computerized information systems to prevent adverse drug events. Proc. AMIA Annu. Fall. Symp., 1997, 228-232.Anderson J.G., Jay S.J., Anderson M., Hunt T.J. Evaluating the potential effectiveness of using computerized information systems to prevent adverse drug events. Proc. AMIA Annu. Fall. Symp., 1997, 228-232.Briceland L.L. Medication errors: an expose of the problem. Medscape Pharmacists, 2000.Briceland L.L. Medication errors: an expose of the problem. Medscape Pharmacists, 2000.Brennan T.A. The Institute of Medicine report on medical errors - could it do harm? N Engl. J. Med. 2000, 342, 1123-1125.Brennan T.A. The Institute of Medicine report on medical errors - could it do harm? N Engl. J. Med. 2000, 342, 1123-1125.Brennan T.A., Leape L.L., Laird N. et al. Incidence of adverse events and negligence in hospitalized patients: results from the Harvard Medical Practice Study I. N Engl. J. Med. 1991, 324, 370-376.Brennan T.A., Leape L.L., Laird N. et al. Incidence of adverse events and negligence in hospitalized patients: results from the Harvard Medical Practice Study I. N Engl. J. Med. 1991, 324, 370-376.Dunn E.B., Wolfe J.J. Unclear dose equals toxic dose. Vet. Hum. Toxicol., 1998, 40(5), 291-293.Dunn E.B., Wolfe J.J. Unclear dose equals toxic dose. Vet. Hum. Toxicol., 1998, 40(5), 291-293.Woosley R.L., Chen Y., Freiman J.P., Gillis R.A. Mechanism of the cardiotoxic actions of terfenadine. JAMA, 1993, 269(12), 1532-1536.Woosley R.L., Chen Y., Freiman J.P., Gillis R.A. Mechanism of the cardiotoxic actions of terfenadine. JAMA, 1993, 269(12), 1532-1536.Olsen P.M., Lorentzen H., Thomsen K., Fogtmann A. Medication errors in a pediatric department. Ugeskr Laeger, 1997, 14, 159(16), 2392-2395.Olsen P.M., Lorentzen H., Thomsen K., Fogtmann A. Medication errors in a pediatric department. Ugeskr Laeger, 1997, 14, 159(16), 2392-2395.Tissot E., Cornette C., Demoly P., Jacquet M., Barale F., Capellier G. Medication Errors at the Administration Stage in an Intensive Care Unit. Intensive Care. Med., 1999, 25(4), 353-359.Tissot E., Cornette C., Demoly P., Jacquet M., Barale F., Capellier G. Medication Errors at the Administration Stage in an Intensive Care Unit. Intensive Care. Med., 1999, 25(4), 353-359.Kohn L.T., Corrigan J.M., Donaldson M.S. Institute of Medicine Report: To Err is Human: Building a Safer Health System. Washington, DC: National Academy Press, November 29, 1999.Kohn L.T., Corrigan J.M., Donaldson M.S. Institute of Medicine Report: To Err is Human: Building a Safer Health System. Washington, DC: National Academy Press, November 29, 1999.Kohn L.T., Corrigan J.M., Donaldson M.S. eds. To Err Is Human: Building a Safer Health System. Institute of Medicine Report, November 29, 1999.Kohn L.T., Corrigan J.M., Donaldson M.S. eds. To Err Is Human: Building a Safer Health System. Institute of Medicine Report, November 29, 1999.Haig K. One Hospital’s Journey Toward Patient Safety, Medscape Money & Medicine, 20034(2).Haig K. One Hospital’s Journey Toward Patient Safety, Medscape Money & Medicine, 20034(2).Kohn L.T., Corrigan J.M., Donaldson M.S. eds. Institute of Medicine Report: To Err is Human: Building a Safer Health System. Washington, DC: National Academy Press, November 29, 1999.Kohn L.T., Corrigan J.M., Donaldson M.S. eds. Institute of Medicine Report: To Err is Human: Building a Safer Health System. Washington, DC: National Academy Press, November 29, 1999.Seeger J.D., Kong S.X., Schumock G.T. Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients. Pharmacotherapy, 1998, 18(6), 1284-1289.Seeger J.D., Kong S.X., Schumock G.T. Characteristics associated with ability to prevent adverse drug reactions in hospitalized patients. Pharmacotherapy, 1998, 18(6), 1284-1289.Leape L., Bates D.W., Cullen D.J. et al. Systems analysis of adverse drug events, JAMA, 1995, 274, 35-43.Leape L., Bates D.W., Cullen D.J. et al. Systems analysis of adverse drug events, JAMA, 1995, 274, 35-43.Schousboe L.P., Tandrup O. Correct documentation of drug prescriptions. Ugeskr. Laeger. 1999, 2, 161(31), 4389-4392.Schousboe L.P., Tandrup O. Correct documentation of drug prescriptions. Ugeskr. Laeger. 1999, 2, 161(31), 4389-4392.Mc Bride W.G. Thalidomide and congenital abnormalities. Lancet, 1961, 2, 1358.Mc Bride W.G. Thalidomide and congenital abnormalities. Lancet, 1961, 2, 1358.Wiholm B.E., Olsson S., Moore N., Waller P. Spontaneous Reporting Systems Outside the US. Pharmacoepidemiology, Third Edition by B.L.Strom, 2000, p.175-192.Wiholm B.E., Olsson S., Moore N., Waller P. Spontaneous Reporting Systems Outside the US. Pharmacoepidemiology, Third Edition by B.L.Strom, 2000, p.175-192.Olsson S. The Role of the WHO Programme on international drug monitoring in coordinating wordwide drug safety efforts. Drug Safety, 1998, 19, 1-10.Olsson S. The Role of the WHO Programme on international drug monitoring in coordinating wordwide drug safety efforts. Drug Safety, 1998, 19, 1-10.Olsson S. ed. National Pharmacovigilance Systems, 2nd edn. Uppsala Monitoring Crntre, 1998.Olsson S. ed. National Pharmacovigilance Systems, 2nd edn. Uppsala Monitoring Crntre, 1998.Фитилев С.Б. Служба безопасности лекарств в российской Федерации // Новая аптека, 1998, 13-19.Фитилев С.Б. Служба безопасности лекарств в российской Федерации // Новая аптека, 1998, 13-19.Edwards I.R. International drug monitoring. In: Aronson J.K., Van Boxtel C.J. Side effects of drugs annual. Vol. 19. Amsterdam: Elsevier Science Publishers, 1995, 450-455.Edwards I.R. International drug monitoring. In: Aronson J.K., Van Boxtel C.J. Side effects of drugs annual. Vol. 19. Amsterdam: Elsevier Science Publishers, 1995, 450-455.Meyboom R. et al. Principles of signal detection in pharmacovigilance, Drug safety, Reprint collection, 2001, 355-365.Meyboom R. et al. Principles of signal detection in pharmacovigilance, Drug safety, Reprint collection, 2001, 355-365.Vere D.W. Drug adverse reactions as masquereders. Adverse Drug Reaction Bull., 1976, 60, 208-211.Vere D.W. Drug adverse reactions as masquereders. Adverse Drug Reaction Bull., 1976, 60, 208-211.Моисеев В.С. Врачебные ошибки. Факторы объективные и субъективные. Когда возможна юридическая ответственность врача // Практикующий врач, 1996, 4, 2, 54-55.Моисеев В.С. Врачебные ошибки. Факторы объективные и субъективные. Когда возможна юридическая ответственность врача // Практикующий врач, 1996, 4, 2, 54-55.Мелихов О.Г. Клинические исследования. М.: Атмосфера, 2003.Мелихов О.Г. Клинические исследования. М.: Атмосфера, 2003.Kubota K. Prescription-event monitoring in Japan (J-PEM), Drug Saf. 2002, 25(6), 441-444.Kubota K. Prescription-event monitoring in Japan (J-PEM), Drug Saf. 2002, 25(6), 441-444.Grahame Smith D.G., Aronson K.K. (eds.). Clinical pharmacology and drug therapy. Oxford Texbook Publishing. Oxford, 1992.Grahame Smith D.G., Aronson K.K. (eds.). Clinical pharmacology and drug therapy. Oxford Texbook Publishing. Oxford, 1992.Rawlins M.D., Thomson J.W. Pathogenesis of adverse drug reactions. In: Textbook of Adverse Drug Reactions. Daires D.M. (Ed.)/ Oxford University Press., 1977, 18-45.Rawlins M.D., Thomson J.W. Pathogenesis of adverse drug reactions. In: Textbook of Adverse Drug Reactions. Daires D.M. (Ed.)/ Oxford University Press., 1977, 18-45.Rene J. Royer. Mechanism of Adverse Drug Reactions: An Overview. Pharmacoepidemiology and drug safety, 1997, 3, 43-50.Rene J. Royer. Mechanism of Adverse Drug Reactions: An Overview. Pharmacoepidemiology and drug safety, 1997, 3, 43-50.Астахова А.В., Лепахин В.К., Брайцева Е.В. Методы выявления неблагоприятных побочных реакций (НПР) лекарств // Безопасность лекарств, 2000, № 2, с. 5-16.Астахова А.В., Лепахин В.К., Брайцева Е.В. Методы выявления неблагоприятных побочных реакций (НПР) лекарств // Безопасность лекарств, 2000, № 2, с. 5-16.Edwards I.R., Aronson J.K. Adverse drug reactions: definitions, diagnosis, and management. Lancet, 2000, 7, 356(9237), 1255-1259.Edwards I.R., Aronson J.K. Adverse drug reactions: definitions, diagnosis, and management. Lancet, 2000, 7, 356(9237), 1255-1259.Edwards R., Biriell C. Harmonisation in Pharmacovigilance, Reprint cjllection 2001, 93-102.Edwards R., Biriell C. Harmonisation in Pharmacovigilance, Reprint cjllection 2001, 93-102.Meyboom R., Lindquist M., Egberts A. An ABC of Drug-Related problems, Drug safety, Reprint collection, 2001, 415-423.Meyboom R., Lindquist M., Egberts A. An ABC of Drug-Related problems, Drug safety, Reprint collection, 2001, 415-423.Davis D.M., editor. Textbook of adverse drug reaction. 4-th ed. Oxford University Press, 1991.Davis D.M., editor. Textbook of adverse drug reaction. 4-th ed. Oxford University Press, 1991.Inmann W. Monitoring for drug safety. 2-nd ed. Lancaster: MTP Press, 1986.Inmann W. Monitoring for drug safety. 2-nd ed. Lancaster: MTP Press, 1986.Kessler D.A. Introducing Med Watch, using FDA form 3500, a new approach to reporting medication and device adverse effects and product problems. JAMA. 1993, 269, 2765-2768.Kessler D.A. Introducing Med Watch, using FDA form 3500, a new approach to reporting medication and device adverse effects and product problems. JAMA. 1993, 269, 2765-2768.Дьюкс М.Н.Г. Контроль лекарств – профессиональная и юридическая ответственность // V Российский национальный конгресс 'Человек и лекарство': Тезисы докладов. М., 1998, с. 549.Дьюкс М.Н.Г. Контроль лекарств – профессиональная и юридическая ответственность // V Российский национальный конгресс 'Человек и лекарство': Тезисы докладов. М., 1998, с. 549.Knowles S., Shapiro L., Shear N.H. Serious dermatologic reactions in children. Curr.Opin.Pediatr., 1997, Aug, 9(4), 388-395.Knowles S., Shapiro L., Shear N.H. Serious dermatologic reactions in children. Curr.Opin.Pediatr., 1997, Aug, 9(4), 388-395.Fletcher A.P. Spontaneous adverse drug reaction reporting vs. event reporting vs. event monitoring: a comparison. J. Roy. Soc. Med., 1991, 84, 341-344.Fletcher A.P. Spontaneous adverse drug reaction reporting vs. event reporting vs. event monitoring: a comparison. J. Roy. Soc. Med., 1991, 84, 341-344.Астахова А.В., Брайцева Е.В., Лепахин В.К. Контроль безопасности лекарственных средств // Фармация, 2000, 4, 38-40.Астахова А.В., Брайцева Е.В., Лепахин В.К. Контроль безопасности лекарственных средств // Фармация, 2000, 4, 38-40.Фитилев С.Б. Карта-извещение как основной инструмент системы контроля побочных действий лекарственных средств // Материалы образовательного семинара 'Контроль безопасности лекарств' VI Всероссийского национального конгресса 'Человек и лекарство', 1999, 35-43.Фитилев С.Б. Карта-извещение как основной инструмент системы контроля побочных действий лекарственных средств // Материалы образовательного семинара 'Контроль безопасности лекарств' VI Всероссийского национального конгресса 'Человек и лекарство', 1999, 35-43.Lanctot K.L., Naranjo C.A. Computer-assisted evaluation of adverse events using a Bayesian approach. J. Clin. Pharmacol., 1994, 34, 142-147.Lanctot K.L., Naranjo C.A. Computer-assisted evaluation of adverse events using a Bayesian approach. J. Clin. Pharmacol., 1994, 34, 142-147.Waller P. Measuring the frequency of adverse drug reactions. Br. J. Clin. Pharmacol., 1992, 33, 249-252.Waller P. Measuring the frequency of adverse drug reactions. Br. J. Clin. Pharmacol., 1992, 33, 249-252.Newby D. An introduction to ADRs. Curr. Therap., 1995, September, 95-97.Newby D. An introduction to ADRs. Curr. Therap., 1995, September, 95-97.Inman W.H.W. Requirements for risk benefit assessment of drugs before withdrawal. B.I.R.A. J., 1986, 5 (2), 11-15.Inman W.H.W. Requirements for risk benefit assessment of drugs before withdrawal. B.I.R.A. J., 1986, 5 (2), 11-15.Mitchell A., Henry D., Hennrikus D., OўConnell D. Adverse Drug Reactions: Can consumers provide early warning? Pharmacoepidemiol. Drug Safe, 1994, 3, 257-264.Mitchell A., Henry D., Hennrikus D., OўConnell D. Adverse Drug Reactions: Can consumers provide early warning? Pharmacoepidemiol. Drug Safe, 1994, 3, 257-264.Inmam W.H.W., Rawson N.S.B., Wilton L.V. Monitoring for drug safety, 1985, 213 p.Inmam W.H.W., Rawson N.S.B., Wilton L.V. Monitoring for drug safety, 1985, 213 p.Davies H., Crombie I. Что такое мета-анализ? // Клин. фармакол. и терапия, 1999, 8 (6), 52-56.Davies H., Crombie I. Что такое мета-анализ? // Клин. фармакол. и терапия, 1999, 8 (6), 52-56.Meyboom R. et al. Causal or casuas? The role of causality assessment in pharmacovigilance, Drug safety, Reprint collection, 2001, 374-389.Meyboom R. et al. Causal or casuas? The role of causality assessment in pharmacovigilance, Drug safety, Reprint collection, 2001, 374-389.Хайде Б. ван дер. Экспорт медикаментов в развивающиеся страны: проблемы остаются нерешенными // Монитор основных лекарств, 1995, 4, 6-7.Хайде Б. ван дер. Экспорт медикаментов в развивающиеся страны: проблемы остаются нерешенными // Монитор основных лекарств, 1995, 4, 6-7.Shashindran C.H., Sethuraman K.R. Продвижение лекарств на рынок: проталкивать, продвигать или обучать? // Монитор основных лекарств, 1995, 4, 24.Shashindran C.H., Sethuraman K.R. Продвижение лекарств на рынок: проталкивать, продвигать или обучать? // Монитор основных лекарств, 1995, 4, 24.Wilkes M.S., Bell R.A., Kravitz R.L. Direct-to-consumer prescription drug advertising: trends, impact, and implications. Health Aff ( Millwood) 2000, 19(2), 110-128.Wilkes M.S., Bell R.A., Kravitz R.L. Direct-to-consumer prescription drug advertising: trends, impact, and implications. Health Aff ( Millwood) 2000, 19(2), 110-128.Zuger A. Fever pitch: getting doctors to prescribe is big business. New York Times, 1999, Jan 11, А1, А13.Zuger A. Fever pitch: getting doctors to prescribe is big business. New York Times, 1999, Jan 11, А1, А13.Van Maaren P.J.M. Dutch druds in developing countries. Styx Publication, Nothern Centre for Health Care, University of Gronibgen, 1994.Van Maaren P.J.M. Dutch druds in developing countries. Styx Publication, Nothern Centre for Health Care, University of Gronibgen, 1994.Чекалаева И.И. Фальсификация лекарственных средств – проблема решаемая // Новая аптека, 2001, 6, 48 –51.Чекалаева И.И. Фальсификация лекарственных средств – проблема решаемая // Новая аптека, 2001, 6, 48 –51.Государственный контроль качества лекарственных средств: состояние и проблемы // Фармацевтический вестник, 1999, 3, 4.Государственный контроль качества лекарственных средств: состояние и проблемы // Фармацевтический вестник, 1999, 3, 4.Захарочкина Е.Р., Битерякова А.М. Рынок антагонистов кальция. Ремедиум, 1998, 11-12, 106-108.Захарочкина Е.Р., Битерякова А.М. Рынок антагонистов кальция. Ремедиум, 1998, 11-12, 106-108.Викулова С. Биоэквивалентность и дженерики: Созданы друг для друга // Ремедиум, 1999, 30 – 32.Викулова С. Биоэквивалентность и дженерики: Созданы друг для друга // Ремедиум, 1999, 30 – 32.World Medical Declaration of Helsinki as amended in Hong. Kong. 1989.World Medical Declaration of Helsinki as amended in Hong. Kong. 1989.World Medical Declaration of Helsinki as amended in Somerset. West, Republic of South Africa, 1996.World Medical Declaration of Helsinki as amended in Somerset. West, Republic of South Africa, 1996.
The authors declare that there are no conflicts of interest present.